The Basal Forebrain Cholinergic Projection
... show immunoreactivity for the apoptotic signal Fasassociated death domain and for abnormally phosphorylated tau protein, the loss of calbindin and concomitant increase of intracellular Ca2þ may be an important process in the pathologic cascade leading to degeneration of basal forebrain cholinergic n ...
... show immunoreactivity for the apoptotic signal Fasassociated death domain and for abnormally phosphorylated tau protein, the loss of calbindin and concomitant increase of intracellular Ca2þ may be an important process in the pathologic cascade leading to degeneration of basal forebrain cholinergic n ...
Full-Text PDF
... (CNS) in rat and human specimens under physiological conditions [12]. Additionally, main thrombin regulatory factors such as FX, protease nexin-1 (PN-1), AT III and thrombin-activated receptors have been identified in these specimens, indicating a potential role of thrombin in the CNS [13]. Prothrom ...
... (CNS) in rat and human specimens under physiological conditions [12]. Additionally, main thrombin regulatory factors such as FX, protease nexin-1 (PN-1), AT III and thrombin-activated receptors have been identified in these specimens, indicating a potential role of thrombin in the CNS [13]. Prothrom ...
Axonal degeneration as a therapeutic target in the CNS | SpringerLink
... nerves, which degenerate in PD and in Lewy body disease. Moreover, here, distal axonal degeneration precedes the loss of their mother neurons. Interestingly, alpha-synuclein aggregates are even more frequent in incidental Lewy body disease, in which tyrosine-hydroxylase-positive neurons are still pr ...
... nerves, which degenerate in PD and in Lewy body disease. Moreover, here, distal axonal degeneration precedes the loss of their mother neurons. Interestingly, alpha-synuclein aggregates are even more frequent in incidental Lewy body disease, in which tyrosine-hydroxylase-positive neurons are still pr ...
The use of antipsychotic medication for people with dementia: Time
... behavioural problems in dementia have grown by chance rather than by specific planning or commissioning and there are important gaps in services and skills. Current systems appear to deliver a largely antipsychotic-based response. The first antipsychotic drugs were produced as a treatment for schizo ...
... behavioural problems in dementia have grown by chance rather than by specific planning or commissioning and there are important gaps in services and skills. Current systems appear to deliver a largely antipsychotic-based response. The first antipsychotic drugs were produced as a treatment for schizo ...
The thalamus as a putative biomarker in neurodegenerative disorders
... (HD), frontotemporal dementia (FTD) and Alzheimer’s disease (AD) for instance, where there is subcortical neuronal loss (Looi and Walterfang, 2012; Looi et al., 2012). A parallel ...
... (HD), frontotemporal dementia (FTD) and Alzheimer’s disease (AD) for instance, where there is subcortical neuronal loss (Looi and Walterfang, 2012; Looi et al., 2012). A parallel ...
The WHO ICD - Short version
... Please note that despite the similarity of the terms, ‘Chronic fatigue syndrome’ which is indexed to G93.3, a code indicating neurological disease, is not the same as ‘Fatigue syndrome’ classified under F48.0 as a mental disorder. 7. ICD-10 and Combined Terms ‘ME/CFS’ and ‘CFS/ME’ No version of the ...
... Please note that despite the similarity of the terms, ‘Chronic fatigue syndrome’ which is indexed to G93.3, a code indicating neurological disease, is not the same as ‘Fatigue syndrome’ classified under F48.0 as a mental disorder. 7. ICD-10 and Combined Terms ‘ME/CFS’ and ‘CFS/ME’ No version of the ...
Alzheimer's disease
Alzheimer's disease (AD), also known as Alzheimer disease, or just Alzheimer's, accounts for 60% to 70% of cases of dementia. It is a chronic neurodegenerative disease that usually starts slowly and gets worse over time. The most common early symptom is difficulty in remembering recent events (short-term memory loss). As the disease advances, symptoms can include problems with language, disorientation (including easily getting lost), mood swings, loss of motivation, not managing self care, and behavioural issues. As a person's condition declines, they often withdraw from family and society. Gradually, bodily functions are lost, ultimately leading to death. Although the speed of progression can vary, the average life expectancy following diagnosis is three to nine years.The cause of Alzheimer's disease is poorly understood. About 70% of the risk is believed to be genetic with many genes usually involved. Other risk factors include a history of head injuries, depression, or hypertension. The disease process is associated with plaques and tangles in the brain. A probable diagnosis is based on the history of the illness and cognitive testing with medical imaging and blood tests to rule out other possible causes. Initial symptoms are often mistaken for normal ageing. Examination of brain tissue is needed for a definite diagnosis. Mental and physical exercise, and avoiding obesity may decrease the risk of AD. There are no medications or supplements that decrease risk.No treatments stop or reverse its progression, though some may temporarily improve symptoms. Affected people increasingly rely on others for assistance, often placing a burden on the caregiver; the pressures can include social, psychological, physical, and economic elements. Exercise programs are beneficial with respect to activities of daily living and can potentially improve outcomes. Treatment of behavioral problems or psychosis due to dementia with antipsychotics is common but not usually recommended due to there often being little benefit and an increased risk of early death.In 2010, there were between 21 and 35 million people worldwide with AD. It most often begins in people over 65 years of age, although 4% to 5% of cases are early-onset Alzheimer's which begin before this. It affects about 6% of people 65 years and older. In 2010, dementia resulted in about 486,000 deaths. It was first described by, and later named after, German psychiatrist and pathologist Alois Alzheimer in 1906. In developed countries, AD is one of the most financially costly diseases.